By Natalie Weger
Stereotaxis shares were higher after the company said it has received Food and Drug Administration clearance for its robotically navigated high-density electrophysiology mapping catheter.
Shares were up 8% at $2.44 on Monday. The stock has been up 7.7% this year.
The medical technology company said its MAGiC Sweep catheter advances the technology available to diagnose and treat complex arrhythmia patients. The MAGiC Sweep would be the first robotically navigated high-density mapping catheter, the company said.
Stereotaxis said high-density mapping has transformed the electrophysiology field by enhancing cardiac ablation procedures through more precise identification of arrhythmia origin.
Write to Natalie Weger at natalie.weger@wsj.com
(END) Dow Jones Newswires
July 28, 2025 10:53 ET (14:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。